托西莫单抗(131I-tositumomab)是一种免疫调节抗肿瘤药 商品名: Bexxar 百克沙 Bexxar 131I-Tositumomab 其他名称:Bexxar。 作用机制:131I-Tositumomab是一种鼠抗CD20抗体IgG2a,用131I标记.131I能释放B和Y射线.作用机制包括抗体介导的细胞毒作用和细胞靶向放射免疫治疗。 主要适应症:化疗无效,CD20阳性,分化低的非霍奇金淋巴瘤。 Tositumomab (Bexxar®) Usage: Tositumomab (Bexxar®) is a monoclonal antibody treatment targeted at the CD20 antigen. Tositumomab is used in the treatment of relapsed or refractory (treatment resistant) Non-Hodgkin's Lymphoma. Tositumomab is administered as 2 sets of infusions, a non-radioactive antibody and then a radioactive antibody. (1) Mechanism: This treatment is different from most antibody-based treatmets. In this case, the antibody has been permanently linked to a radioactive form of iodine (I131). The antibody is used to deliver the radioactive iodine to cancer cells which are then destroyed by the radiation. This form of treatment is termed radioimmunotherapy. Note that the image shown is a general structure of an antibody. There are four proteins bound together in a 'Y' shape. The two top tips of the Y are where the antibody binds with its target. This means that each antibody molecule can bind to two identical target regions. Side Effects: The most common side effect associated with tositumomab treatment is lowered blood cell count. Other common side effects include: weakness, fever, nausea, infection, cough. Severe allergic reactions may also occur. Patients who have already received murine proteins and may have mounted an anti-mouse immune response are at a higher risk for a reaction of this sort. In some patients hypothyroidism (reduced thyroid gland function) may occur. For this reason thyroid blocking agents must be administered with tositumomab. Treatment and screening for hypothyroidism should continue on an annual basis after treatment ends. Because this therapy includes a radioactive material that is inside the body for some period of time, patients should be given special instructions and precautions to prevent harm to any other person. Contraindications: Patients should not become pregnant while undergoing tositumomab therapy and therapy should not be given before pregnancy is ruled out. Contraception should be used by males and females during and 12 months after treatment has ended. 百克沙处方资料 其他名称:Bexxar。 作用机制:131I-Tositumomab是一种鼠抗CD20抗体IgG2a,用131I标记.131I能释放B和Y射线.作用机制包括抗体介导的细胞毒作用和细胞靶向放射免疫治疗。 主要适应症:化疗无效,CD20阳性,分化低的非霍奇金淋巴瘤。 常用剂量及方案:在放射和治疗剂量前,先给予醋酸酚650mg和苯海拉明50mg.碘化钾饱和液2~3滴,口服每日3次,放射剂量前24小时开始服用,治疗剂量结束后再服用14天.以防止甲状腺摄取131I。 1 放射测定剂量:先给予未标记的Tositumomab,450mg静滴1小时,继以131I-Tositumomab 2 治疗剂量:先给予未标记的Tositumomab450mg,静滴1小时,然后给予病人最适剂量的131I-Tositumomab35mg(平均90 mCi,范围为50-200 mCi)。 注意事项: 1) 淋巴瘤骨髓侵犯超过25%,骨髓外照射超过25%或有HAMAS(HACAS)病者慎用。 2) 放疗前24小时口服碘化钾饱和液,每天3次,每次2~3滴,连用14天。 毒性反应: 1 骨髓抑制和其他血液学毒性:髓系抑制十分常见。20%病人出现IV级血小板减少或中性粒细胞减少。 2 恶心,呕吐和其他胃肠道反应:恶心常见,呕吐,腹痛和厌食偶见。 3 皮肤粘膜反应:瘙痒,皮疹偶见。 4 其他: 1)可能发生HAMAS或HACAS。 [-产地国家-] 美国 |
托西莫单抗(131I-tositumomab)简介:
托西莫单抗(131I-tositumomab)是一种免疫调节抗肿瘤药
商品名: Bexxar
百克沙 Bexxar 131I-Tositumomab 其他名称:Bexxar。 作用机制:131I-Tositumomab是一种鼠抗CD20抗体IgG2a,用131I标记.131I能 ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多 |